Your prediction
Pros and Cons of LogicBio Therapeutics Inc in the next few years
Pros
?
S********** s********
?
C******** o* t** e**********
?
G***** c******* t* c**********
Cons
?
W********* I********* f** t** n*** y****
?
B****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of LogicBio Therapeutics Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| LogicBio Therapeutics Inc | - | -2.532% | 0.000% | - | 26.230% | - | - |
| Pacira Pharmaceuticals | 2.800% | 4.902% | 7.000% | 15.676% | 15.676% | -44.271% | -54.661% |
| Rockwell Medical Inc. | -2.440% | -5.729% | 2.046% | -58.951% | -60.417% | -16.440% | -92.115% |
| Twist Bioscience Corp | -0.570% | -5.009% | 14.014% | -41.746% | -42.357% | 6.269% | -77.276% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2025-04-26
ContextLogic Inc. (LOGC) presents a challenging financial picture as of the 2024 annual report. The company's financial health is characterized by significant losses, declining revenue, and negative cash flows. Key findings include:
The overall financial trend is negative, driven by declining revenue and persistent losses.
Investors should carefully consider these factors when evaluating ContextLogic Inc., focusing on the company's ability to address its declining revenue and return to profitability.